Research project Fatigue is one of the most common symptoms in patients in the chronic phase of traumatic brain injury (TBI). Despite the frequency of fatigue, and its impact on the daily life of these patients, there are no evidencebased treatments for this symptoms, nor any objective ways for diagnosis.
OSU6162 showed safe to use, causing only minor side effects. However, there were no treatment effects on fatigue after 4 weeks of treatment at a maximum dose of 15 mg twice daily. fMRI revealed effects of treatment with OSU6162, but only in regions not related to fatigue. fMRI showed that fatigue after TBI is related to alterations in striato-thalamic-cortical loops. The differences in BOLD signal in the caudate nucleus showed high diagnostic accuracy with a sensitivity of 81% and a specificity of 91%.
Berginström N, Nordström P, Schuit R, Nordström A. The Effects of (−)-OSU6162 on Chronic Fatigue in Patients With Traumatic Brain Injury: A Randomized Controlled Trial. Journal of Head Trauma Rehabilitation 2017; 32(2): E46-E54.
Berginström N, Nordström P, Ekman U, Eriksson J, Andersson M, Nyberg L, Nordström A. Fatigue after traumatic brain injury is linked to altered striato-thalamic-cortical functioning. Brain Injury: Accepted Abstracts from the International Brain Injury Association's 12th World Congress on Brain Injury, 2017;31: 755-755
Berginström N, Nordström P, Ekman U, Eriksson J, Andersson M, Nyberg L, Nordström A. Using Functional Magnetic Resonance Imaging to Detect Chronic Fatigue in Patients With Previous Traumatic Brain Injury: Changes Linked to Altered Striato-Thalamic-Cortical Functioning. Journal of Head Trauma Rehabilitation 2018; 33(4): 266-274.
Berginström N, Nordström P, Ekman U, Eriksson J, Nyberg L, Nordström A. Pharmaco-fMRI in Patients with Traumatic Brain Injury: A Randomized Controlled Trial with the Monoaminergic Stabilizer (-)-OSU6162. Journal of Head Trauma Rehabilitation 2018. Published Ahead of Print. doi: 10.1097/HTR.0000000000000440